NYSE:IQVIqvia Stock Price, Forecast & News

Iqvia's stock was trading at $125.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IQV shares have increased by 28.6% and is now trading at $161.23.
View which stocks have been most impacted by COVID-19.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 1 hold rating and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Iqvia.

Iqvia is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Iqvia.

Iqvia Holdings Inc (NYSE:IQV) posted its quarterly earnings data on Wednesday, July, 22nd. The medical research company reported $1.18 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.06 by $0.12. The medical research company earned $2.52 billion during the quarter, compared to the consensus estimate of $2.41 billion. Iqvia had a net margin of 1.21% and a return on equity of 17.90%. During the same quarter in the previous year, the firm posted $1.53 EPS.
View Iqvia's earnings history.

Iqvia issued an update on its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share guidance of $6.10-6.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.87. The company issued revenue guidance of $11.0-11.1 billion, compared to the consensus revenue estimate of $10.73 billion.

17 equities research analysts have issued 1-year price objectives for Iqvia's shares. Their forecasts range from $110.00 to $200.00. On average, they expect Iqvia's stock price to reach $165.00 in the next twelve months. This suggests a possible upside of 2.3% from the stock's current price.
View analysts' price targets for Iqvia.

Press coverage about IQV stock has been trending somewhat negative this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iqvia earned a news impact score of -1.8 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Iqvia.

Iqvia saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 2,870,000 shares, a decline of 17.3% from the April 15th total of 3,470,000 shares. Based on an average daily trading volume, of 1,980,000 shares, the days-to-cover ratio is currently 1.4 days. Currently, 1.5% of the company's stock are sold short.
View Iqvia's Short Interest.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), Syneos Health (SYNH), PRA Health Sciences (PRAH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Luna Innovations (LUNA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), NVIDIA (NVDA), Chipotle Mexican Grill (CMG), Endologix (ELGX), Alibaba Group (BABA), Micron Technology (MU), Paypal (PYPL), Accenture (ACN) and salesforce.com (CRM).

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.75%), BlackRock Inc. (7.22%), Jackson Square Partners LLC (2.05%), FMR LLC (1.09%), Bessemer Group Inc. (0.92%) and Winslow Capital Management LLC (0.87%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer, Ronald E Bruehlman and W Richard Staub.
View institutional ownership trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Goldman Sachs Group Inc., FMR LLC, Marshall Wace LLP, Macquarie Group Ltd., Marshall Wace North America L.P., Prudential Financial Inc., and Strs Ohio. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Group Holdings (Sbs) Advis Tpg, John Connaughton, Michael J Evanisko, and Michael R Mcdonnell.
View insider buying and selling activity for Iqvia.

IQV stock was acquired by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Vanguard Group Inc., State of Tennessee Treasury Department, Nordea Investment Management AB, Bessemer Group Inc., Alyeska Investment Group L.P., Veracity Capital LLC, and Ninety One North America Inc..
View insider buying and selling activity for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $161.23.

Iqvia has a market capitalization of $30.84 billion and generates $11.09 billion in revenue each year. The medical research company earns $191 million in net income (profit) each year or $5.94 on an earnings per share basis. Iqvia employs 67,000 workers across the globe.

The official website for Iqvia is www.iqvia.com.

Iqvia's mailing address is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]